A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
A phase 3 trial of Trifluridine/tipiracil in colorectal cancer, run by Jiangsu Simcere Pharmaceutical Co., Ltd., now recruiting.
Overview
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT07361003 by Jiangsu Simcere Pharmaceutical Co., Ltd., with 464 participants planned, started 2025-11-12 and due to reach its primary completion in 2028-01. Interventions recorded: Suvemcitug injection, trifluridine/tipiracil tablets, Suvemcitug placebo injection, trifluridine/tipiracil tablets. Conditions listed: Refractory Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
Shares Trifluridine/tipiracil, Colorectal cancer.
- TrialTATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Shares Trifluridine/tipiracil, Colorectal cancer.
- TrialNelmastobart in Combination With Trifluridine/ Tipiracil and Bevacizumab in Metastatic/ Recurrent Colorectal Cancer
Shares Trifluridine/tipiracil, Colorectal cancer.
- TrialSUNLIGHT
Shares Trifluridine/tipiracil, Colorectal cancer.
- TrialInjection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu,
Shares Trifluridine/tipiracil, Colorectal cancer.
- TrialFOG-001 in Locally Advanced or Metastatic Solid Tumors
Shares Trifluridine/tipiracil, Colorectal cancer.
- PersonTae Won Kim
Shares Trifluridine/tipiracil, Colorectal cancer.
- CompanyServier
Shares Trifluridine/tipiracil, Colorectal cancer.